Silexion posts positive SIL204 pancreatic data

Silexion Therapeutics Corp filed a current report describing a new press release about its oncology candidate SIL204.

Rhea-AI Filing Summary

Silexion Therapeutics Corp filed a current report describing a new press release about its oncology candidate SIL204. On September 11, 2025, the company reported positive preclinical data showing SIL204’s reach and activity in major pancreatic cancer metastatic sites after systemic administration. The press release is included as Exhibit 99.1 and incorporated by reference for additional scientific details. The disclosure is furnished under Regulation FD, meaning it is intended to provide broad, non-selective access to this research update without being treated as filed financial information.

Insights

Biotech and SEC disclosure analyst

Silexion furnishes positive preclinical SIL204 data via Regulation FD.

The report centers on a press release where Silexion Therapeutics describes positive preclinical results for SIL204 in pancreatic cancer metastasis models following systemic dosing. This suggests the drug candidate demonstrated activity and tissue reach in key metastatic sites, an important early hurdle for systemic oncology therapies.

The information is furnished under Item 7.01 (Regulation FD), which emphasizes broad, simultaneous disclosure rather than financial reporting. Because the detailed data, study design, and next development steps are contained in the attached press release, subsequent scientific and clinical updates in later periods will be needed to understand how this preclinical signal may influence the overall development path for SIL204.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Silexion Therapeutics Corp (SLXN) disclose in this 8-K?

Silexion Therapeutics Corp furnished a press release reporting positive preclinical data for its candidate SIL204 in major pancreatic cancer metastatic sites following systemic administration.

What is the focus of Silexion (SLXN) candidate SIL204 in this filing?

The filing highlights preclinical results where SIL204 showed reach and activity in major pancreatic cancer metastatic sites after systemic administration, as described in the attached press release.

Under which SEC item did Silexion (SLXN) provide this information?

The company furnished the information under Item 7.01, Regulation FD Disclosure, indicating it is being shared for broad, non-selective investor access.

Does the Silexion Therapeutics 8-K include detailed SIL204 data?

The 8-K itself summarizes the news and attaches the full press release as Exhibit 99.1, which contains the detailed description of the SIL204 preclinical results.

Are the SIL204 preclinical results considered filed financial information?

No. Silexion states that the information in Item 7.01 and the press release is furnished, not deemed "filed" for purposes of Section 18 of the Exchange Act.

What exhibits are attached to this Silexion (SLXN) 8-K?

The report includes Exhibit 99.1, a press release dated September 11, 2025, and Exhibit 104, the cover page interactive data file in Inline XBRL.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/11/2025 - 07:31 AM Learn about SEC filing dates

false000202241600-0000000972NASDAQNASDAQ00020224162025-09-112025-09-110002022416slxn:OrdinarySharesParValue00135PerShareMember2025-09-112025-09-110002022416slxn:WarrantsExercisableForOrdinarySharesAtAnExercisePriceOf155250PerShareMember2025-09-112025-09-11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): September 11, 2025

Silexion Therapeutics Corp
(Exact name of registrant as specified in its charter)

Cayman Islands		001-42253		N/A
(State or other jurisdiction		(Commission File Number)		(I.R.S. Employer
of incorporation)				Identification No.)

12 Abba Hillel Road Ramat-Gan, Israel		5250606
(Address of principal executive offices)		(Zip Code)

+972-3-7564999

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Ordinary Shares, par value $0.0135 per share		SLXN		The Nasdaq Stock Market LLC
Warrants exercisable for Ordinary Shares at an exercise price of $1,552.50 per share		SLXNW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On September 11, 2025, Silexion Therapeutics Corp issued a press release entitled “Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204’s Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration.” A copy of the press release is furnished with this Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

The information in Item 7.01 of this Form 8-K, including the information in the press release furnished pursuant to this Item 7.01 of Form 8-K, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Furthermore, the information in Item 7.01 of this Form 8-K, including the information in the press release, shall not be deemed to be incorporated by reference in the filings of the registrant under the Securities Act of 1933, as amended.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1	Press Release dated September 11, 2025
104	Cover Page Interactive Data File (formatted in Inline XBRL)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SILEXION THERAPEUTICS CORP
Date: September 11, 2025	By: /s/ Ilan Hadar
	Name:	Ilan Hadar
	Title:	Chief Executive Officer